- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07227012
Une étude pour en apprendre davantage sur le médicament d'étude appelé PF-08634404 en tant que traitement unique et en association chez des participants adultes atteints d'un cancer du foie appelé carcinome hépatocellulaire, qui est trop avancé pour être retiré par chirurgie et peut s'être propagé à d'autres parties du corps.
UNE ÉTUDE INTERVENTIONNELLE OUVERTE DE PHASE 1B/2 ÉVALUANT LA SÉCURITÉ, LA PHARMACOCINÉTIQUE ET L'EFFICACITÉ PRÉLIMINAIRE DU PF-08634404 EN MONOTHÉRAPIE ET EN THÉRAPIE COMBINÉE CHEZ DES PARTICIPANTS ADULTES ATTEINTS D'UN CARCINOME HÉPATOCELLULAIRE LOCALEMENT AVANCÉ NON RÉSÉQUABLE OU MÉTSTATIQUE
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
- Be 18 years or older.
- Have locally advanced or metastatic HCC.
- Is not a candidate for complete surgical or loco-regional therapies.
- Have not received any whole-body treatment for HCC.
Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Pfizer CT.gov Call Center
- Numéro de téléphone: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200032
- Recrutement
- Zhongshan Hospital,Fudan University
-
-
-
-
-
Fukuoka, Japon, 811-1395
- Recrutement
- National Hospital Organization Kyushu Cancer Center
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 464-8681
- Recrutement
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa, Chiba, Japon, 277-8577
- Recrutement
- National Cancer Center Hospital East
-
-
Osaka
-
Sakai, Osaka, Japon, 590-0197
- Recrutement
- Kindai University Hospital- Osaka Medical Campus
-
-
Tokyo
-
Chuo-ku, Tokyo, Japon, 104-0045
- Recrutement
- National Cancer Center Hospital
-
-
-
-
-
San Juan, Porto Rico, 00909
- Recrutement
- Pan American Center for Oncology Trials, LLC
-
-
United States of America
-
Dorado, United States of America, Porto Rico, 00646
- Recrutement
- Pan American Center for Oncology Trials, LLC - Dorado Office
-
Mayagüez, United States of America, Porto Rico, 00680
- Recrutement
- Pan American Center for Oncology Trials, LLC - Mayaguez Office
-
Ponce, United States of America, Porto Rico, 00730
- Recrutement
- Pan American Center for Oncology Trials, LLC - Ponce Office
-
-
-
-
-
Taichung, Taïwan, 407
- Recrutement
- Taichung Veterans General Hospital
-
Tainan, Taïwan, 704
- Recrutement
- National Cheng Kung University Hospital
-
Taipei, Taïwan, 10002
- Recrutement
- National Taiwan University Hospital
-
Taipei, Taïwan, 112
- Recrutement
- Taipei Veterans General Hospital
-
-
-
-
California
-
Irvine, California, États-Unis, 92612
- Recrutement
- Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Irvine, California, États-Unis, 92612
- Recrutement
- UCI Health - Irvine Infusion Pharmacy ACC
-
Irvine, California, États-Unis, 92612
- Recrutement
- UCI Health - Irvine
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- Keck Hospital of USC
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- USC/Norris Comprehensive Cancer Center / Investigational Drug Services
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- Los Angeles General Medical Center
-
Los Angeles, California, États-Unis, 90025
- Recrutement
- START Los Angeles, LLC
-
Los Angeles, California, États-Unis, 90067
- Recrutement
- LACN Century City
-
Orange, California, États-Unis, 92868
- Recrutement
- UC Irvine Health - Chao Family Comprehensive Cancer Center
-
Pasadena, California, États-Unis, 91105
- Recrutement
- Keck Medical Center of USC Pasadena
-
-
Florida
-
Land O' Lakes, Florida, États-Unis, 34638
- Recrutement
- Moffitt Cancer Center at Speros
-
Ruskin, Florida, États-Unis, 33570
- Recrutement
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- Moffitt Cancer Center - McKinley Campus
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- Moffitt Cancer Center
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- Moffitt McKinley Hospital
-
Tampa, Florida, États-Unis, 33607
- Recrutement
- Moffitt Cancer Center - International Plaza
-
Wesley Chapel, Florida, États-Unis, 33544
- Recrutement
- Moffitt Cancer Center at Wesley Chapel
-
-
Illinois
-
Shiloh, Illinois, États-Unis, 62269
- Recrutement
- Siteman Cancer Center - Shiloh
-
Shiloh, Illinois, États-Unis, 62269
- Recrutement
- Memorial Hospital
-
-
Minnesota
-
Coon Rapids, Minnesota, États-Unis, 55433
- Recrutement
- Allina Health Cancer Institute - Mercy Hospital
-
Minneapolis, Minnesota, États-Unis, 55407
- Recrutement
- Allina Health Cancer Institute - Abbott Northwestern Hospital
-
Saint Paul, Minnesota, États-Unis, 55102
- Recrutement
- Allina Health Cancer Institute - United Hospital
-
-
Missouri
-
City of Saint Peters, Missouri, États-Unis, 63376
- Recrutement
- Siteman Cancer Center - St. Peters
-
Creve Coeur, Missouri, États-Unis, 63141
- Recrutement
- Siteman Cancer Center - West County
-
Florissant, Missouri, États-Unis, 63031
- Recrutement
- Siteman Cancer Center - North County
-
Kansas City, Missouri, États-Unis, 64111
- Recrutement
- Saint Luke's Hospital of Kansas City
-
Kansas City, Missouri, États-Unis, 64111
- Recrutement
- Saint Luke's Cancer Institute
-
St Louis, Missouri, États-Unis, 63108
- Recrutement
- Siteman Cancer Center
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Washington University School of Medicine - Siteman Cancer Center
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Barnes-Jewish Hospital
-
St Louis, Missouri, États-Unis, 63129
- Recrutement
- Siteman Cancer Center - South County
-
-
Nevada
-
Reno, Nevada, États-Unis, 89502
- Recrutement
- Renown Regional Medical Center
-
Reno, Nevada, États-Unis, 89502
- Recrutement
- Renown Health Medical Oncology
-
Reno, Nevada, États-Unis, 89502
- Recrutement
- Renown Office of Clinical Research
-
-
North Carolina
-
Cary, North Carolina, États-Unis, 27518
- Recrutement
- Duke Cancer Center Cary
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke Cancer Center
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University - Main Hospital and Clinics
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke Cancer Center - Investigational Chemotherapy Service
-
Raleigh, North Carolina, États-Unis, 27609
- Recrutement
- Duke Cancer Center Raleigh
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Recrutement
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Recrutement
- AHN Allegheny General Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Recrutement
- AHN Cancer Institute at Allegheny General Hospital
-
-
Washington
-
Seattle, Washington, États-Unis, 98101
- Recrutement
- Virginia Mason Medical Center
-
Seattle, Washington, États-Unis, 98109
- Recrutement
- Fred Hutchinson Cancer Center
-
Seattle, Washington, États-Unis, 98195
- Recrutement
- University of Washington Medical Center- Montlake
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 18 years of age or older at screening.
- Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
- Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
- Adequate hepatic, liver, and renal function
- No prior systemic therapy for HCC.
- ECOG performance status 0 or 1
- Child-Pugh Class A
Key Exclusion Criteria:
- Moderate or severe ascites.
- History of hepatic encephalopathy.
- Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
- Clinically significant risk of hemorrhage or fistula.
- Participants with any history of another malignancy within 3 years.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
- Clinically significant cardiovascular disease within 6 months prior to the first dose.
- Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
- History of severe bleeding tendency or coagulation dysfunction.
- History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
- Participants with acute, chronic or symptomatic infections.
- Participants with history of immunodeficiency.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase 1b
Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab. |
Solution for infusion Solution for infusion
Autres noms:
|
|
Expérimental: Phase 2
Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab. |
Solution for infusion Solution for infusion
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Adverse Events
Délai: Through end of study and up to approximately 24 months
|
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through end of study and up to approximately 24 months
|
|
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
Délai: Through 90 days after the last dose of study intervention; Approximately 24 months
|
DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period. |
Through 90 days after the last dose of study intervention; Approximately 24 months
|
|
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Délai: Approximately 24 months
|
ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
Délai: Approximately 24 months
|
The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2. |
Approximately 24 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Délai: Approximately 24 months
|
ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Duration of Response (DOR) per RECIST 1.1 by investigator
Délai: Approximately 24 months
|
DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 by investigator
Délai: Approximately 24 months
|
PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Overall Survival (OS)
Délai: Approximately 24 months
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 24 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
Délai: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
|
Pharmacokinetics (PK): Serum concentrations of PF-08634404
Délai: Up to 24 months
|
Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
|
Incidence of antidrug antibody against PF-08634404
Délai: Up to 24 months
|
To evaluate immunogenicity of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Pfizer CT.gov Call Center, Pfizer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies du foie
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Carcinome
- Carcinome hépatocellulaire
- Tumeurs du foie
- Acides aminés, peptides et protéines
- Protéines
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Ipilimumab
Autres numéros d'identification d'étude
- C6461013
- 2025-523525-17-00 (Ctis)
- Symbiotic-GI-13 (Autre identifiant: Pfizer)
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .